Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TOP2A | P11388 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13742763 | 0.94 | CYP1A2 (0.64) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2115655 | 0.84 | PIN1 (0.64) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24846509 | 0.80 | CYP1A2 (0.88) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6115542 | 0.79 | CYP1A2 (0.38) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6948069 | 0.79 | MPO (0.47) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL432160 | 0.79 | PAK1 (0.48) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6946759 | 0.79 | CYP2D6 (0.48) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9872850 | 0.77 | ALDH1A1 (0.45) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8826177 | 0.77 | SLC29A1 (0.47) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6950876 | 0.76 | MPO (0.56) | CYP2D6CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085017-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2019-03-21 | — | — | US | disclosed |
| US-20170145046-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170145046-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Biocodex, Inc (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Biocodex, Inc (US) | 2014-01-30 | — | — | US | disclosed |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP2B, TOP1 | CYP2D6 237/4885CYP1A2 462/4885CYP3A4 765/4885 |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP1, TOP2B | CYP2D6 93/4885CYP1A2 183/4885CYP3A4 944/4885 |
| US-20190085017-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP1, TOP2B | CYP2D6 95/4885CYP1A2 177/4885CYP3A4 929/4885 |
| US-20170145046-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOP2A, TOP1, TOP2B | CYP2D6 91/4885CYP1A2 168/4885CYP3A4 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.